

Supplementary Information

Carbon nanotube-ruthenium hybrid towards mild oxidation of sulfides to sulfones: Efficient synthesis of diverse sulfonyl compounds

Renata G. Almeida,^a Renato L. de Carvalho,^a Mateus P. Nunes,^a Roberto S. Gomes,^b
Leandro F. Pedrosa,^c Carlos A. de Simone,^d Elumalai Gopi,^e Valérie Geertsen,^f Edmond
Gravel,^e Eric Doris^{e*} and Eufrânio N. da Silva Júnior^{a*}

^a*Institute of Exact Sciences, Department of Chemistry, Federal University of Minas
Gerais, Belo Horizonte, MG, 31270-901, Brazil;*

^b*Department of Chemistry and Chemical Biology, Harvard University, USA;*

^c*Fluminense Federal University, Volta Redonda, RJ, 27213-145, Brazil.*

^d*Institute of Physics, University of São Paulo, São Carlos, SP, 13560-160, Brazil.*

^e*Service de Chimie Bioorganique et de Marquage (SCBM) CEA, Université Paris-
Saclay 91191 Gif-sur-Yvette, France.*

^f*NIMBE, CEA, CNRS, Université Paris-Saclay, 91191, Gif-sur-Yvette, France*

Corresponding authors: eufranio@ufmg.br, eric.doris@cea.fr


Contents

A) General experimental details.....	S2
B) Synthesis of substrates and known compounds	S2
C) General procedure for the thiolation reactions	S3
D) General procedure for oxidation with RuCNT/NaIO ₄	S10
E) Example of substrate and its respective product of oxidation solved by X-ray crystallography	S17
F) Synthesis of BODIPY	S20
G) Procedure for the recycling experiments and TEM analysis	S24
H) Copies of NMR spectra of novel compounds	S25
I) Copies of HRMS of novel compounds.....	S58

General experimental details

Unless otherwise indicated, all common reagents and solvents were used as obtained from commercial suppliers without further purification. Flash column chromatography (FCC) was performed using silica gel (Aldrich 40-63 μm , 230-400 mesh). Thin layer chromatography (TLC) was performed using aluminium backed 60 F254 silica plates. Visualization was achieved by UV fluorescence. Proton nuclear magnetic resonance spectra (NMR) were recorded using Bruker DRX 400, Bruker AVANCE 400 or Bruker AVANCE NEO ASCEND 600. ^{13}C NMR spectra were recorded at 100 MHz or at 150 MHz as stated. Chemical shifts (δ) are given in parts per million (ppm). Peaks are described as singlets (s), doublets (d), double doublets (dd), triplets (t), double triplets (dt), and multiplets (m). ^1H and ^{13}C NMR spectra were referenced to the appropriate residual solvent peak or TMS peak. Coupling constants (J) were quoted to the nearest 0.5 Hz. Mass spectra were recorded using a Bruker microTOFII ESI spectrometer (ESI⁺ mode). Infrared spectra were recorded on a Perkin Elmer Spectrum One FTIR spectrometer as thin films or solids compressed on a diamond plate. IR bands ($\bar{\nu}$, cm^{-1}) are described as strong (s), medium (m) and weak (w). Melting points were determined using Stuart SMP30 melting point apparatus and are uncorrected.


Synthesis of AgSCF_3 ¹



To an oven dried 30 mL Schlenk flask equipped with a stir bar 2.5 g (19,7 mmol) of dry AgF was added. The flask was evacuated and refilled with Argon (three times) until inert atmosphere was achieved. 15 mL of dry MeCN was injected into the flask followed by 2.5 mL of CS₂. The flask was then placed into a pre-heated at 80 °C oil bath with efficient stirring. After 14 h, the reaction mixture was black, and the mixture was allowed to cool to room temperature. MeCN and the excess of CS₂ were removed under reduced pressure with the aid of a rotary evaporator to produce a black residue, which was then dissolved in EtOAc and filtered through a pad of celite. The solvent was once again removed under reduced pressure and the resulting yellow solid was dissolved in a minimum amount of MeCN to produce a clear yellow solution. 30 mL of


Et₂O was carefully layered on top of the yellow solution. The flask was placed in a freezer set to -10°C for 24 h to produce off-white crystals. The crystals were collected by filtration, dried under reduced pressure, affording AgSCF₃ (1.25 g, 5.98 mmol, 90%). **m.p.** (°C) = 224.8-225.9 (degrades) (Et₂O/CH₃CN).

General procedure for the synthesis of AgSR salts:²




A 50 mL round bottom flask was charged with the corresponding thiol (2.0 mmol), EtN₃ (2.0 mmol, 279 μL) and acetonitrile (5 mL). The mixture was stirred and a solution of AgNO₃ (339.7 mg, 2 mmol) in acetonitrile (10 mL) was added dropwise. The suspension was stirred for 30 min under vigorous stirring, and the resulting solid was filtered, washed with acetonitrile (30 mL) and dried under reduced pressure. Yields for all AgSR salts were quantitative.


General procedure for the thiolation reactions:³




An oven dried re-sealable reaction tube was charged with the corresponding iodinated quinone (0.20 mmol), AgSR (0.20 mmol) and CuTc (1.6 mg, 5 mol%). Anhydrous DMAc (2.0 mL) was added and the tube was sealed. The mixture was heated at 100 °C for 18 h. After cooling and solvent removal by reduced pressure, the residue was purified by FCC, under the conditions noted.




7-((Trifluoromethylthio)-1,6-anthraquinone (1a): Purification by FCC (toluene) afforded product **1a** (56.7 mg, 0.18 mmol, 92% yield) as yellow solid; **m.p.** (°C) = 173-175; **IR (solid, cm⁻¹)** ν : 1671 (w), 1274 (m), 1098 (s), 698 (s); **HRMS (ESI⁺):** Calcd for C₁₅H₈F₃O₂SNa [M+Na]⁺ 331.0011, found 331.0011; **¹H NMR (400 MHz, CDCl₃)** δ : 8.27 (d, J = 7.5 Hz, 3H), 7.99 (d, J = 8.2 Hz, 1H), 7.91-7.70 (m, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.9, 182.1, 135.3, 134.6, 134.5, 133.9, 133.2, 132.5, 132.2 (dd, J = 6.1, 3.1 Hz), 131.1, 129.7, 128.0, 127.5, 127.2, 126.2. The data are consistent with those reported in the literature.³




1-(Phenylthio)anthracene-9,10-dione (1b): Purification by FCC (toluene) afforded product **1b** (53.8 mg, 0.17 mmol, 85% yield) as orange solid; **m.p.** (°C) = 173-175; **IR (solid, cm⁻¹)** ν : 3068 (s), 2165 (w), 1979 (w), 1666 (s), 1442 (m), 1417 (m), 962 (w), 698 (w); **HRMS (ESI⁺):** Calcd for C₂₀H₁₂O₂SNa [M+Na]⁺ 339.0455, found 339.0457; **HRMS (ESI⁺):** Calcd for C₂₀H₁₃O₂S [M+H]⁺ 317.0636, found 317.0640; **¹H NMR (400 MHz, CDCl₃)** δ : 8.38 (d, J = 7.5 Hz, 1H), 8.28 (d, J = 7.4 Hz, 1H), 8.09 (d, J = 7.5 Hz, 1H), 7.90-7.71 (m, 2H), 7.64 (dd, J = 6.3, 2.9 Hz, 2H), 7.57-7.47 (m, 3H), 7.44 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H). **¹³C NMR (101 MHz, CDCl₃)** δ : 183.6, 183.1, 146.5, 136.1, 135.1, 134.4, 134.0, 133.8, 132.8, 132.7, 131.9, 131.9, 130.1, 129.8, 128.1, 127.5, 126.9, 124.1.




1-((4-Bromophenyl)thio)anthracene-9,10-dione (1c): Purification by FCC (toluene) afforded product **1c** (53.7 mg, 0.14 mmol, 68% yield) as orange solid; **m.p.** (°C) = 192-195; **IR (solid, cm⁻¹)** ν : 3075 (w), 1662 (s), 1647 (m), 1567 (s), 704 (s), 658 (s); **HRMS (ESI⁺):** Calcd for C₂₀H₁₁BrO₂SNa [M+Na]⁺ 416.9560, found 416.9558; **HRMS (ESI⁺):** Calcd for C₂₀H₁₂BrO₂S [M+H]⁺ 394.9741, found 394.9745; **¹H NMR (400 MHz, CDCl₃)** δ : 8.36 (d, J = 7.5 Hz, 1H), 8.28 (d, J = 7.2 Hz, 1H), 8.10 (d, J = 7.5 Hz, 1H), 7.92-7.70 (m, 2H), 7.63 (d, J = 8.2 Hz, 2H), 7.48 (dd, J = 15.1, 7.7 Hz, 3H), 7.09 (d, J = 8.2 Hz, 1H). **¹³C NMR (101 MHz, CDCl₃)** δ : 183.6, 182.9, 145.5, 137.6, 135.1, 134.4, 133.9, 133.3, 132.9, 132.7, 131.7, 131.2, 128.2, 127.5, 127.4, 126.9, 124.6, 124.3.




1-(p-Tolylthio)anthracene-9,10-dione (1d): Purification by FCC (toluene) afforded product **1d** (64.9 mg, 0.19 mmol, 97% yield) as orange solid; **m.p.** (°C) = 213-215; **IR (solid, cm⁻¹)** ν : 3040 (w), 1664 (s), 1569 (s), 1417 (w), 802 (s), 705 (s); **HRMS (ESI⁺):** Calcd for C₂₁H₁₄O₂SNa [M+Na]⁺ 353.0612, found 353.0616; **HRMS (ESI⁺):** Calcd for C₂₁H₁₅O₂S [M+H]⁺ 331.0792, found 331.0799; **¹H NMR (400 MHz, CDCl₃)** δ : 8.37 (d, J = 7.4 Hz, 1H), 8.27 (d, J = 7.4 Hz, 1H), 8.06 (d, J = 7.5 Hz, 1H), 7.95-7.72 (m, 2H), 7.51 (d, J = 7.6 Hz, 2H), 7.43 (t, J = 7.9 Hz, 1H), 7.30 (d, J = 7.6 Hz, 2H), 7.11 (d, J = 8.2 Hz, 1H), 2.44 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.5, 183.1, 146.9, 140.1, 136.1, 135.1, 134.3, 134.1, 134.0, 133.7, 132.7, 132.7, 131.8, 130.8, 128.3, 128.0, 127.5, 127.2, 126.9, 123.9, 21.4.




1-((4-Methoxyphenyl)thio)anthracene-9,10-dione (1e): Purification by FCC (toluene) afforded product **1e** (62.3 mg, 0.18 mmol, 90% yield) as red solid; **m.p.** (°C) = 210-213; **IR (solid, cm⁻¹)** ν : 2919 (w), 1665 (s), 1592 (s), 1568 (s), 1493 (m), 802 (s), 701 (s); **HRMS (ESI⁺)**: Calcd for C₂₁H₁₄O₃SNa [M+Na]⁺ 369.0561, found 369.0559; **HRMS (ESI⁺)**: Calcd for C₂₁H₁₅O₃S [M+H]⁺ 347.0741, found 347.0739; **¹H NMR (400 MHz, CDCl₃)** δ : 8.38 (d, *J* = 7.7 Hz, 1H), 8.28 (d, *J* = 7.3 Hz, 1H), 8.08 (d, *J* = 7.5 Hz, 1H), 7.81 (dt, *J* = 15.7, 7.9 Hz, 2H), 7.54 (d, *J* = 8.6 Hz, 2H), 7.45 (t, *J* = 7.9 Hz, 1H), 7.11 (d, *J* = 8.2 Hz, 1H), 7.02 (d, *J* = 8.6 Hz, 2H), 3.88 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.6, 183.2, 161.0, 147.5, 137.7, 135.1, 134.4, 134.1, 134.0, 133.8, 132.7, 132.7, 131.7, 127.9, 127.5, 126.9, 123.9, 122.4, 115.7, 55.5.




1-(Benzylthio)anthracene-9,10-dione (1f): Purification by FCC (toluene) afforded product **1f** (44.3 mg, 0.13 mmol, 67% yield) as orange solid; **m.p.** (°C) = 173-175; **IR (solid, cm⁻¹)** ν : 2923 (m), 1668 (m), 1271 (m), 704 (s); **HRMS (ESI⁺)**: Calcd for C₂₁H₁₅O₂SNa [M+Na]⁺ 353.0612, found 353.0613; **HRMS (ESI⁺)**: Calcd for C₂₁H₁₅O₂S [M+H]⁺ 331.0792, found 331.0781; **¹H NMR (400 MHz, CDCl₃)** δ : 8.31 (dd, *J* = 17.7, 7.5 Hz, 2H), 8.16 (d, *J* = 7.4 Hz, 1H), 7.81 (dd, *J* = 13.9, 7.2 Hz, 2H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.68 (t, *J* = 7.8 Hz, 1H), 7.50 (d, *J* = 7.5 Hz, 2H), 7.38 (t, *J* = 7.4 Hz, 2H), 7.32 (d, *J* = 7.3 Hz, 1H), 4.28 (s, 2H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.5, 183.1, 145.3, 135.4, 134.3, 133.9, 133.7, 133.1, 132.5, 130.1, 129.2, 128.8, 127.8, 127.6, 127.5, 126.8, 124.9, 123.6, 37.5. The data are consistent with those reported in the literature.³




1-(*m*-Tolylthio)anthracene-9,10-dione (1g): Purification by FCC (toluene) afforded product **1g** (52.8 mg, 0.16 mmol, 80% yield) as orange solid; **m.p.** (°C) = 167-169; **IR (solid, cm⁻¹)** ν : 2920 (m), 1669 (s), 1569 (m), 1309 (m), 697 (s); **HRMS (ESI⁺):** Calcd for C₂₁H₁₄O₂SNa [M+Na]⁺ 353.0612, found 353.0615; **HRMS (ESI⁺):** Calcd for C₂₁H₁₅O₂S [M+H]⁺ 331.0792, found 331.0797; **¹H NMR (400 MHz, CDCl₃)** δ : 8.36 (d, *J* = 7.5 Hz, 1H), 8.27 (d, *J* = 7.4 Hz, 1H), 8.06 (d, *J* = 7.5 Hz, 1H), 7.88-7.69 (m, 2H), 7.54-7.34 (m, 4H), 7.30 (d, *J* = 7.4 Hz, 1H), 7.12 (d, *J* = 8.2 Hz, 1H), 2.41 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.4, 183.0, 146.6, 140.0, 136.6, 135.0, 134.3, 133.9, 133.7, 133.0, 132.7, 132.6, 131.9, 131.5, 130.6, 129.8, 127.9, 127.4, 126.8, 124.0, 21.3.




1-((3-Chlorophenyl)thio)anthracene-9,10-dione (1h): Purification by FCC (toluene) afforded product **1h** (53.3 mg, 0.15 mmol, 76% yield) as orange solid; **m.p.** (°C) = 159-161; **IR (solid, cm⁻¹)** ν : 3061 (w), 1668 (s), 1592 (m), 1567 (s), 725 (s), 699 (s); **HRMS (ESI⁺):** Calcd for C₂₀H₁₁ClO₂SNa [M+Na]⁺ 373.0066, found 373.0071; **HRMS (ESI⁺):** Calcd for C₂₀H₁₂ClO₂S [M+H]⁺ 351.0246, found 351.0251; **¹H NMR (400 MHz, CDCl₃)** δ : 8.36 (d, *J* = 7.7 Hz, 1H), 8.28 (d, *J* = 8.3 Hz, 1H), 8.10 (d, *J* = 7.5 Hz, 1H), 7.90-7.74 (m, 2H), 7.64 (s, 1H), 7.58-7.39 (m, 4H), 7.10 (d, *J* = 8.2 Hz, 1H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.6, 182.9, 145.3, 135.7, 135.6, 135.1, 134.4, 134.2, 134.0, 133.9, 133.8, 133.0, 132.6, 131.8, 131.1, 130.1, 128.2, 127.5, 127.0, 124.4.




1-(3-Methoxyphenylthio)anthracene-9,10-dione (1i): Purification by FCC (toluene) afforded product **1i** (62.3 mg, 0.18 mmol, 90% yield) as orange solid; **m.p.** (°C) = 118-121; **IR (solid, cm⁻¹)** ν : 3071 (w), 1668 (s), 1587 (m), 1569 (s), 802 (s), 701 (s); **HRMS (ESI⁺)**: Calcd for C₂₁H₁₄O₃SNa [M+Na]⁺ 369.0561, found 369.0567; **HRMS (ESI⁺)**: Calcd for C₂₁H₁₅O₃S [M+H]⁺ 347.0741, found 347.0747; **¹H NMR (400 MHz, CDCl₃)** δ : 8.37 (d, J = 7.6 Hz, 1H), 8.27 (d, J = 7.3 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.94-7.67 (m, 2H), 7.49-7.36 (m, 2H), 7.23 (d, J = 7.5 Hz, 1H), 7.20-7.13 (m, 2H), 7.04 (dd, J = 8.2, 1.7 Hz, 1H), 3.83 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.5, 183.0, 160.6, 146.3, 135.0, 134.3, 134.0, 133.8, 132.9, 132.8, 132.7, 132.0, 130.9, 128.2, 127.5, 126.9, 124.1, 120.8, 116.0, 55.4.



1-(Ethylthio)anthracene-9,10-dione (1j): Purification by FCC (toluene) afforded product **1j** (26.3 mg, 0.01 mmol, 49% yield) as orange solid; **m.p.** (°C) = 165-167; **IR (solid, cm⁻¹)** ν : 3071 (w), 2925 (m), 1662 (s), 1595 (w), 1567 (s), 1311 (s); **HRMS (ESI⁺)**: Calcd for C₁₆H₁₂O₂SNa [M+Na]⁺ 291.0455, found 291.0450; **HRMS (ESI⁺)**: Calcd for C₁₆H₁₃O₂S [M+H]⁺ 269.0636, found 269.0639; **¹H NMR (400 MHz, CDCl₃)** δ : 8.30 (d, J = 7.7 Hz, 1H), 8.24 (d, J = 7.3 Hz, 1H), 8.08 (dd, J = 5.9, 2.7 Hz, 1H), 7.85-7.71 (m, 2H), 7.69-7.59 (m, 2H), 3.01 (q, J = 7.4 Hz, 2H), 1.46 (t, J = 7.4 Hz, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.4, 183.1, 145.5, 135.5, 134.3, 134.0, 133.6, 132.9, 132.5, 129.8, 128.7, 127.4, 126.7, 123.3, 26.1, 12.8.




2-Iodo-1-(p-tolylthio)anthracene-9,10-dione (1k): Purification by FCC (hexane:toluene) afforded product **1k** (77.6 mg, 0.17 mmol, 85% yield) as red solid; **m.p.** (°C) = 170-173; **IR (solid, cm⁻¹)** ν : 3062 (w), 1665 (s), 1584 (m), 1549 (s), 1489 (m), 708 (s); **HRMS (ESI⁺)**: Calcd for C₂₁H₁₃IO₂SNa [M+Na]⁺ 478.9578, found 478.9573; **HRMS (ESI⁺)**: Calcd for C₂₁H₁₄IO₂S [M+H]⁺ 456.9759, found 456.9765; **¹H NMR (400 MHz, CDCl₃)** δ : 8.35 (d, *J* = 8.2 Hz, 1H), 8.21 (dd, *J* = 5.7, 3.3 Hz, 1H), 8.04 (dd, *J* = 5.6, 3.4 Hz, 1H), 7.99 (d, *J* = 8.2 Hz, 1H), 7.79-7.70 (m, 2H), 7.02 (s, 4H), 2.26 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 182.6, 182.3, 145.0, 141.4, 136.6, 136.3, 136.2, 135.3, 134.6, 134.5, 133.8, 133.7, 132.2, 129.9, 128.7, 128.3, 127.4, 126.6, 119.4, 21.0.




2-Iodo-1-(phenylthio)anthracene-9,10-dione (1l): Purification by FCC (hexane:toluene) afforded product **1l** (69.8 mg, 0.16 mmol, 79.0% yield) as red solid; **m.p.** (°C) = 148-150; **IR (solid, cm⁻¹)** ν : 2922 (s), 1671 (s), 1662 (s), 1582 (m), 1547 (s), 707 (s); **HRMS (ESI⁺)**: Calcd for C₂₀H₁₁IO₂SNa [M+Na]⁺ 464.9422, found 464.9425; **HRMS (ESI⁺)**: Calcd for C₂₀H₁₂IO₂S [M+H]⁺ 442.9602, found 442.9609; **¹H NMR (400 MHz, CDCl₃)** δ : 8.37 (d, *J* = 8.2 Hz, 1H), 8.26-8.17 (m, 1H), 8.08-7.96 (m, 2H), 7.74 (dd, *J* = 5.7, 3.3 Hz, 2H), 7.21 (t, *J* = 7.5 Hz, 2H), 7.12 (dd, *J* = 15.1, 7.3 Hz, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 182.5, 182.3, 145.1, 140.7, 137.4, 136.7, 135.4, 134.6, 134.6, 133.7, 132.2, 129.2, 128.5, 128.3, 127.4, 126.6, 126.2, 119.7.

General procedure for oxidation with RuCNT/NaIO₄

To a solution of the corresponding sulfide (0.1 mmol) in H₂O:ACN:DCM (2:1:1, 4 mL) was added RuCNT (0.1 mol%, 333 μL of 0.3 mM aqueous suspension). The mixture was kept under vigorous stirring, and NaIO₄ (63.9 mg, 0.3 mmol) was added. The mixture was heated at 75 °C for 1 h, washed with a saturated solution of NaHCO₃ (10 mL) and extracted with CH₂Cl₂ (3 × 10 mL). The organic phase was dried with Na₂SO₄ and submitted to purification by column chromatography over silica-gel, eluting with toluene.




7-((Trifluoromethyl)sulfonyl)-1,6-anthraquinone (2a): Purification by FCC (toluene) afforded product **2a** (33.0 mg, 0.097 mmol, 97% yield) as yellow solid; **m.p.** (°C) = 214.9-216.0; **IR (solid, cm⁻¹)** ν : 2923 (w), 1685 (m), 1190 (s), 704 (s); **HRMS (ESI⁺):** Calcd for C₁₅H₇F₃O₄SNa [M+Na]⁺ 362.9914, found 362.9913; **HRMS (ESI⁺):** Calcd for C₁₅H₈F₃O₄S [M+H]⁺ 341.0095, found 341.0099; **¹H NMR (400 MHz, CDCl₃)** δ : 8.78 (d, *J* = 7.8 Hz, 1H), 8.73 (d, *J* = 7.9 Hz, 1H), 8.38-8.28 (m, 2H), 8.07 (t, *J* = 7.9 Hz, 1H), 7.97-7.81 (m, 2H). **¹³C NMR (100 MHz, CDCl₃)** δ : 181.0, 180.8, 138.3, 135.9, 135.1, 134.9, 134.6, 134.0, 133.4, 132.1, 128.0, 127.3. The data are consistent with those reported in the literature.³




1-(Phenylsulfonyl)anthracene-9,10-dione (2b): Purification by FCC (toluene) afforded product **2b** (34.8 mg, 0.1 mmol, >99% yield) as yellow solid; **m.p.** (°C) = 218-


221; **IR (solid, cm⁻¹)** ν : 3074 (s), 1684 (s), 1670 (m), 1578 (m), 1304 (s), 1153 (s), 748 (w), 688 (s); **HRMS (ESI⁺)**: Calcd for C₂₀H₁₂O₄SNa [M+Na]⁺ 371.0354, found 371.0353; **HRMS (ESI⁺)**: Calcd for C₂₀H₁₃O₄S [M+H]⁺ 349.0534, found 349.0533; **¹H NMR (400 MHz, CDCl₃)** δ : 8.96 (d, *J* = 7.8 Hz, 1H), 8.68 (d, *J* = 7.8 Hz, 1H), 8.22 (dd, *J* = 5.7, 2.9 Hz, 1H), 8.15 (dd, *J* = 5.7, 3.1 Hz, 1H), 8.04 (dd, *J* = 7.0, 5.0 Hz, 3H), 7.81-7.71 (m, 2H), 7.63-7.46 (m, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 181.8, 181.0, 141.8, 141.5, 136.8, 135.8, 134.7, 134.3, 133.8, 133.5, 132.7, 132.0, 128.6, 127.8, 127.5, 126.9.




1-((4-Bromophenyl)sulfonyl)anthracene-9,10-dione (2c): Purification by FCC (toluene) afforded product **2c** (33.3 mg, 0.78 mmol, 78% yield) as yellow solid; **m.p.** (°C) = 215-218; **IR (solid, cm⁻¹)** ν : 3080 (s), 1673 (s), 1573 (s), 1388 (m), 808 (s), 701 (s), 664 (w); **HRMS (ESI⁺)**: Calcd for C₂₀H₁₁O₄BrSNa [M+Na]⁺ 448.9459, found 448.9458; **HRMS (ESI⁺)**: Calcd for C₂₀H₁₂O₄BrS [M+H]⁺ 425.9561, found 425.9568; **¹H NMR (400 MHz, CDCl₃)** δ : 8.95 (d, *J* = 7.8 Hz, 1H), 8.69 (d, *J* = 7.7 Hz, 1H), 8.30-8.19 (m, 1H), 8.18-8.13 (m, 1H), 8.05 (t, *J* = 7.8 Hz, 1H), 7.91 (d, *J* = 8.3 Hz, 2H), 7.83-7.76 (m, 2H), 7.67 (d, *J* = 8.3 Hz, 2H). **¹³C NMR (100 MHz, CDCl₃)** δ : 181.7, 181.1, 141.1, 140.9, 136.8, 135.9, 134.8, 134.4, 133.7, 133.6, 133.0, 132.7, 132.0, 131.8, 129.2, 127.8, 127.0.




1-Tosylanthracene-9,10-dione (2d): Purification by FCC (toluene) afforded product **2d** (31.8 mg, 0.088 mmol, 88% yield) as yellow solid; **m.p.** (°C) = 210-212; **IR (solid, cm⁻¹)** ν : 3082 (s), 1675 (s), 1580 (m), 1462 (w), 815 (m), 704 (s); **HRMS (ESI⁺)**: Calcd for C₂₁H₁₄O₄SNa [M+Na]⁺ 385.0510, found 385.0508; **HRMS (ESI⁺)**: Calcd for C₂₁H₁₅O₄S [M+H]⁺ 363.0691, found 363.0692; **¹H NMR (400 MHz, CDCl₃)** δ : 8.93 (d, *J* = 7.9 Hz, 1H), 8.66 (d, *J* = 7.8 Hz, 1H), 8.26-8.20 (m, 1H), 8.17 (dt, *J* = 7.5, 3.7 Hz, 1H), 8.01 (t, *J* = 7.9 Hz, 1H), 7.94 (d, *J* = 8.2 Hz, 2H), 7.83-7.68 (m, 2H), 7.33 (d, *J* = 8.2 Hz, 2H), 2.41 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 181.9, 181.1, 143.7, 142.0, 138.8, 136.7, 135.8, 134.7, 134.2, 133.9, 133.4, 132.8, 132.6, 132.0, 129.2, 127.8, 126.9, 21.6.



1-((4-Methoxyphenyl)sulfonyl)anthracene-9,10-dione (2e): Purification by FCC (toluene) afforded product **2e** (34.4 mg, 0.091 mmol, 91% yield) as yellow solid; **m.p.** (°C) = 220-222; **IR (solid, cm⁻¹)** ν : 2920 (s), 1685 (s), 1666 (m), 1576 (s), 1308 (s), 836 (s), 703 (s); **HRMS (ESI⁺)**: Calcd for C₂₁H₁₄O₅SNa [M+Na]⁺ 401.0459, found 401.0459; **HRMS (ESI⁺)**: Calcd for C₂₁H₁₅O₅S [M+H]⁺ 379.0640, found 379.0639; **¹H NMR (400 MHz, CDCl₃)** δ : 8.90 (dd, *J* = 7.9, 1.2 Hz, 1H), 8.65 (dd, *J* = 7.8, 1.2 Hz, 1H), 8.30-8.15 (m, 2H), 8.10-7.95 (m, 3H), 7.86-7.72 (m, 2H), 7.10-6.94 (m, 2H), 3.86 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 182.0, 181.2, 163.1, 142.5, 136.6, 135.7, 134.7, 134.2, 134.0, 133.4, 133.0, 132.7, 132.5, 132.0, 130.5, 127.8, 126.9, 113.8, 55.6.




5-(Benzylsulfonyl)-1,6-anthraquinone (2f): Purification by FCC (toluene) afforded product **2f** (24.6 mg, 0.068 mmol, 68% yield) as a yellow solid; **m.p.** (°C) = 210-212; **IR (solid, cm⁻¹)** ν : 1680 (m), 1303 (s), 1110 (m), 692 (s); **HRMS (ESI⁺):** Calcd for C₂₁H₁₅O₄SNa [M+Na]⁺ 385.0510 found 385.0513; **HRMS (ESI⁺):** Calcd for C₂₁H₁₅O₄S [M+H]⁺ 363.0686 found 363.0680; **¹H NMR (400 MHz, CDCl₃)** δ : 8.53 (d, *J* = 7.8 Hz, 1H), 8.34 (d, *J* = 7.6 Hz, 1H), 8.29-8.23 (m, 1H), 8.16 (d, *J* = 7.9 Hz, 1H), 7.92-7.81 (m, 2H), 7.71 (t, *J* = 7.9 Hz, 1H), 7.37-7.31 (m, 2H), 7.25 (t, *J* = 5.9 Hz, 3H), 5.25 (s, 2H). **¹³C NMR (100 MHz, CDCl₃)** δ : 183.4, 181.7, 139.8, 137.8, 135.4, 134.9, 134.5, 134.4, 134.1, 133.1, 132.4, 132.2, 131.1, 128.9, 128.7, 128.2, 127.8, 127.1, 62.4. The data are consistent with those reported in the literature.³




1-(*m*-Tolylsulfonyl)anthracene-9,10-dione (2g): Purification by FCC (toluene) afforded product **2g** (21.7 mg, 0.06 mmol, 60% yield) as a yellow solid; **m.p.** (°C) = 204-206; **IR (solid, cm⁻¹)** ν : 3075 (s), 1684 (s), 1670 (m), 1576 (m), 1315 (s), 1148 (m), 787 (s); **HRMS (ESI⁺):** Calcd for C₂₁H₁₄O₄SNa [M+Na]⁺ 385.0510, found 385.0510; **HRMS (ESI⁺):** Calcd for C₂₁H₁₅O₄S [M+H]⁺ 363.0691, found 363.0697; **¹H NMR (400 MHz, CDCl₃)** δ : 8.94 (d, *J* = 7.9 Hz, 1H), 8.67 (d, *J* = 7.8 Hz, 1H), 8.27-8.20 (m, 1H), 8.18-8.13 (m, 1H), 8.03 (t, *J* = 7.9 Hz, 1H), 7.88-7.72 (m, 4H), 7.48-7.34 (m, 2H), 2.43 (s, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 181.9, 181.0, 141.7, 141.5, 138.8, 136.8,

135.8, 134.7, 134.3, 133.8, 133.6, 133.5, 132.8, 132.7, 132.0, 128.4, 127.8, 127.5, 126.9, 124.6, 21.4.




1-((3-Chlorophenyl)sulfonyl)anthracene-9,10-dione (2h): Purification by FCC (toluene) afforded product **2h** (32.2 mg, 0.084 mmol, 84% yield) as a yellow solid; **m.p.** (°C) = 200-203; **IR (solid, cm⁻¹)** ν : 3078 (s), 1682 (s), 1578 (s), 1316 (s), 955 (m), 790 (s); **HRMS (ESI⁺)**: Calcd for C₂₀H₁₁O₄ClSNa [M+Na]⁺ 404.9964, found 404.9967; **HRMS (ESI⁺)**: Calcd for C₂₀H₁₂O₄ClS [M+H]⁺ 383.0144, found 383.0149; **¹H NMR (400 MHz, CDCl₃)** δ : 8.96 (d, *J* = 7.9 Hz, 1H), 8.71 (d, *J* = 7.8 Hz, 1H), 8.27-8.21 (m, 1H), 8.21-8.13 (m, 1H), 8.06 (t, *J* = 7.9 Hz, 1H), 8.00-7.89 (m, 2H), 7.85-7.74 (m, 2H), 7.51 (dt, *J* = 15.6, 7.9 Hz, 2H). **¹³C NMR (100 MHz, CDCl₃)** δ : 181.7, 180.9, 143.7, 140.7, 136.9, 135.9, 134.8, 134.5, 133.7, 133.1, 132.8, 131.9, 129.8, 127.8, 127.4, 127.0, 125.6.




1-((3-Methoxyphenyl)sulfonyl)anthracene-9,10-dione (2i): Purification by FCC (toluene) afforded product **2i** (21.2 mg, 0.056 mmol, 56% yield) as a yellow solid; **m.p.** (°C) = 189-191; **IR (solid, cm⁻¹)** ν : 3077 (s), 1682 (s), 1578 (m), 1478 (m), 1311 (s), 956 (m), 703 (s); **HRMS (ESI⁺)**: Calcd for C₂₁H₁₄O₅SNa [M+Na]⁺ 401.0459, found 401.0457; **HRMS (ESI⁺)**: Calcd for C₂₁H₁₅O₅S [M+H]⁺ 379.0640, found 379.0638; **¹H NMR (400 MHz, CDCl₃)** δ : 8.92 (d, *J* = 7.9 Hz, 1H), 8.67 (d, *J* = 7.8 Hz, 1H), 8.31-

8.20 (m, 1H), 8.19-8.12 (m, 1H), 8.03 (t, $J = 7.9$ Hz, 1H), 7.77 (dd, $J = 5.3, 3.8$ Hz, 2H), 7.61 (s, 1H), 7.50 (d, $J = 7.8$ Hz, 1H), 7.41 (t, $J = 8.0$ Hz, 1H), 7.09 (dd, $J = 8.1, 2.1$ Hz, 1H), 3.90 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 181.8, 180.9, 159.5, 143.1, 141.3, 136.6, 135.8, 134.7, 134.3, 133.8, 133.5, 132.8, 132.7, 131.9, 129.6, 127.8, 126.9, 119.3, 119.0, 112.4, 55.8.




1-(Ethylsulfonyl)anthracene-9,10-dione (2j): Purification by FCC (toluene) afforded product **2j** (21.0 mg, 0.07 mmol, 70% yield) as a yellow solid; **m.p.** ($^{\circ}\text{C}$) = 208-210; **IR (solid, cm^{-1}) ν :** 3092 (s), 1683 (s), 1662 (m), 1575 (m), 1112 (s); **HRMS (ESI $^{+}$):** Calcd for $\text{C}_{16}\text{H}_{12}\text{O}_4\text{SNa}$ $[\text{M}+\text{Na}]^{+}$ 323.0354, found 323.0358; **HRMS (ESI $^{+}$):** Calcd for $\text{C}_{16}\text{H}_{13}\text{O}_4\text{S}$ $[\text{M}+\text{H}]^{+}$ 301.0534, found 301.0537; ^1H NMR (400 MHz, CDCl_3) δ : 8.65 (dd, $J = 7.8, 1.9$ Hz, 2H), 8.30-8.24 (m, 2H), 7.98 (t, $J = 7.9$ Hz, 1H), 7.89-7.81 (m, 2H), 3.99 (q, $J = 7.5$ Hz, 2H), 1.42 (t, $J = 7.5$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 182.9, 181.6, 140.1, 137.5, 135.7, 134.9, 134.5, 134.3, 134.0, 133.5, 132.7, 132.0, 127.7, 127.0, 50.7, 7.6.




2-Iodo-1-tosylanthracene-9,10-dione (2k): Purification by FCC (toluene) afforded product **2k** (29.3 mg, 0.06 mmol, 60% yield) as a light yellow solid; **m.p.** ($^{\circ}\text{C}$) = 220-223; **IR (solid, cm^{-1}) ν :** 3075 (s), 1673 (s), 1596 (m), 1554 (m), 1302 (s), 814 (s), 706 (s); **HRMS (ESI $^{+}$):** Calcd for $\text{C}_{21}\text{H}_{13}\text{IO}_4\text{SNa}$ $[\text{M}+\text{Na}]^{+}$ 510.9477, found 510.9470; **HRMS (ESI $^{+}$):** Calcd for $\text{C}_{21}\text{H}_{14}\text{IO}_4\text{S}$ $[\text{M}+\text{H}]^{+}$ 488.9657, found 488.9655; ^1H NMR

(400 MHz, CDCl₃) δ : 8.44 (d, J = 8.2 Hz, 1H), 8.28 (d, J = 8.2 Hz, 2H), 8.21-8.14 (m, 1H), 8.12-8.06 (m, 2H), 7.84-7.78 (m, 2H), 7.40 (d, J = 8.0 Hz, 2H), 2.47 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 185.1, 181.2, 147.2, 145.9, 144.5, 140.9, 138.0, 135.6, 134.9, 134.6, 133.9, 132.0, 131.1, 129.5, 128.8, 127.0, 126.8, 104.5, 21.7.




2-Iodo-1-(phenylsulfonyl)anthracene-9,10-dione (2I): Purification by FCC (toluene) afforded product **2I** (16.6 mg, 0.035 mmol, 84% yield) as a light yellow solid; **m.p.** (°C) = 228-230; **IR (solid, cm⁻¹)** ν : 3054 (s), 1681 (s), 1575 (m), 1446 (m), 1303 (s), 706 (s); **HRMS (ESI⁺)**: Calcd for C₂₀H₁₁IO₄SNa [M+Na]⁺ 496.9320, found 496.9322; **HRMS (ESI⁺)**: Calcd for C₂₀H₁₂IO₄S [M+H]⁺ 474.9501, found 474.9501; **¹H NMR (400 MHz, CDCl₃)** δ : 8.46 (d, J = 8.2 Hz, 1H), 8.37 (d, J = 7.5 Hz, 2H), 8.25-8.15 (m, 1H), 8.09 (d, J = 8.2 Hz, 1H), 8.06-8.01 (m, 1H), 7.87-7.73 (m, 2H), 7.73-7.60 (m, 3H). **¹³C NMR (100 MHz, CDCl₃)** δ : 182.5, 182.3, 145.1, 140.6, 137.4, 135.3, 134.6, 133.7, 132.2, 129.2, 128.9, 128.5, 128.3, 127.4, 126.6, 126.2, 119.7.




Entry	RuCNT (mol%)	Solvent	Yield (%) ^b
1	0.1	H ₂ O	NR
2	0.1	ACN:H ₂ O (1:1)	NR
3	0.1	DCM:H ₂ O (1:1)	9
4	0.1	H ₂ O:ACN:DCM (2:1:1)	97


Table S1. Oxidation reaction performed with H₂O, ACN:H₂O (1:1), DCM:H₂O (1:1) and H₂O:ACN:DCM (2:1:1) as solvents.

Example of substrate and its respective product of oxidation solved by X-ray crystallography.







(methylsulfonyl)benzene (4a): Purification by recrystallization (hexane/ CHCl_3) afforded product **4b** (31.2 mg, 0.2 mmol, >99% yield) as a crystalline white solid; **m.p.** ($^{\circ}\text{C}$) = 85-87; **IR (solid, cm^{-1}) ν :** 3024 (s), 1448 (m), 1282 (s), 1143 (s), 788 (s), 746 (s), 687 (w); **^1H NMR (400 MHz, CDCl_3) δ :** 7.95 (d, $J = 7.7$ Hz, 2H), 7.67 (t, $J = 7.4$ Hz, 1H), 7.58 (t, $J = 7.6$ Hz, 2H), 3.06 (s, 3H). **^{13}C NMR (100 MHz, CDCl_3) δ :** 140.6, 133.7, 129.4, 127.3, 44.5. The data are consistent with those reported in the literature.⁶




1-methyl-4-(methylsulfonyl)benzene (4b): Purification by recrystallization (hexane/ CHCl_3) afforded product **4b** (31.0 mg, 0.18 mmol, 91% yield) as a crystalline white solid; **m.p.** ($^{\circ}\text{C}$) = 82-84; **IR (solid, cm^{-1}) ν :** 3010 (s), 1448 (m), 1287 (s), 1143 (s), 780 (s), 680 (w); **^1H NMR (400 MHz, CDCl_3) δ :** 7.76 (d, $J = 8.1$ Hz, 2H), 7.30 (d, $J = 8.0$ Hz, 2H), 2.97 (s, 3H), 2.39 (s, 3H). **^{13}C NMR (100 MHz, CDCl_3) δ :** 151.1, 144.6, 129.9, 127.4, 44.6, 21.6. The data are consistent with those reported in the literature.⁷




1-bromo-4-(methylsulfonyl)benzene (4c): Purification by recrystallization (hexane/ CHCl_3) afforded product **4c** (47.1 mg, 0.2 mmol, >99% yield) as a crystalline white solid; **m.p.** ($^{\circ}\text{C}$) = 100-102; **IR (solid, cm^{-1}) ν :** 3093 (s), 1572 (m), 1464 (w), 1306 (s), 823 (s), 660 (w); **^1H NMR (400 MHz, CDCl_3) δ :** 7.82 (d, $J = 8.5$ Hz, 2H), 7.72 (d, $J = 8.6$ Hz, 2H), 3.06 (s, 3H). **^{13}C NMR (150 MHz, CDCl_3) δ :** 139.5, 132.6, 129.0, 128.9, 127.4, 44.4. The data are consistent with those reported in the literature.⁸



1-methoxy-4-(methylsulfonyl)benzene (4d): Purification by recrystallization (hexane/ CHCl_3) afforded product **4d** (37.2 mg, 0.2 mmol, >99% yield) as a crystalline white solid; **m.p.** ($^\circ\text{C}$) = 113-115; **IR (solid, cm^{-1}) ν :** 3010 (s), 1593 (m), 1499 (m), 1290 (s), 833 (s); **$^1\text{H NMR}$ (400 MHz, CDCl_3) δ :** 7.87 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 3.04 (s, 3H). **$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ :** 163.6, 132.2, 129.4, 114.4, 55.6, 44.8. The data are consistent with those reported in the literature.⁶




((methylsulfonyl)methyl)benzene (4e): Purification by recrystallization (hexane/ CHCl_3) afforded product **4e** (22.8 mg, 0.13 mmol, 87% yield) as a crystalline white solid; **m.p.** ($^\circ\text{C}$) = 123-125; **IR (solid, cm^{-1}) ν :** 3013 (s), 1603 (w), 1458 (m), 1412 (m), 1299 (s); **$^1\text{H NMR}$ (400 MHz, CDCl_3) δ :** 7.41 (s, 5H), 4.25 (s, 2H), 2.76 (s, 3H). **$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ :** 130.5, 129.1, 128.2, 61.2, 38.9. The data are consistent with those reported in the literature.⁸




1-chloro-3-(methylsulfonyl)benzene (4f): Purification by recrystallization (hexane/ CHCl_3) afforded product **4f** (25.6 mg, 0.2 mmol, 67% yield) as a crystalline white solid; **m.p.** ($^\circ\text{C}$) = 55-57; **IR (solid, cm^{-1}) ν :** 3028 (s), 1570 (m), 1450 (w), 1306 (s), 823 (s); **$^1\text{H NMR}$ (400 MHz, CDCl_3) δ :** 7.95 (s, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 7.9 Hz, 1H), 3.08 (s, 3H). **$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ :** 142.2, 135.6, 133.9, 130.7, 127.5, 125.5, 44.4. The data are consistent with those reported in the literature.⁶

Synthesis of BODIPY 5'




5,5-difluoro-10-(4-methoxyphenyl)-1,3,7,9-tetramethyl-2,8-bis(phenylthio)-5H-4 λ ⁴,5 λ ⁴-dipyrrolo[1,2-*c*:2',1'-*f*][1,3,2]diazaborinine: To a suspension of *N*-chlorosuccinimide (267 mg, 2 mmol) in CH₂Cl₂ (10 mL) at room temperature was dropwise addition of a solution of thiophenol (220,4 mg, 2 mmol) in dry CH₂Cl₂ (10 mL). After stirring for 30 min, the orange solution of the phenyl-sulfenyl chloride was used *in situ* assuming a complete conversion. The solution the phenyl-sulfenyl chloride at 0 °C, a solution of BODIPY 5' (50,0 mg, 0,135 mmol) in 10 mL of in dry CH₂Cl₂ was added dropwise within 15 min. The mixture of was stirred at room temperature for 15 min. H₂O (20 mL) was added to the deep red reaction mixture. After phase separation, the organic phase was washed with H₂O (20 mL), dried over Na₂SO₄, and the solvent was evaporated under vacuum. The residue was purified through column chromatography on silica, using hexane/CH₂Cl₂ (8:1) as eluent to give the desired product 5.




5,5-difluoro-10-(4-methoxyphenyl)-1,3,7,9-tetramethyl-2,8-bis(phenylsulfonyl)-5H-4 λ ⁴,5 λ ⁴-dipyrrolo[1,2-*c*:2',1'-*f*][1,3,2]diazaborinine (5): Purification by FCC

(hexane/CH₂Cl₂) afforded product **5** (1.07 g, 1.87 mmol, 94% yield) as an pink solid; **m.p.** (°C) = 225-228; **IR (solid, cm⁻¹)** ν : 2930 (m), 1606 (m), 1517 (s), 1289 (s), 1243 (s), 1173 (s), 991 (s), 726 (m), 681 (w); **HRMS (ESI⁺)**: Calcd for C₃₂H₃₀BF₂N₂OS₂ [M+H]⁺ 571.1860, found 571.1842; **¹H NMR (400 MHz, CDCl₃)** δ : 7.24-7.17 (m, 6H), 7.10 (ddd, *J* = 6.9, 2.1, 1.1 Hz, 2H), 7.06-7.02 (m, 2H), 7.00 (dt, *J* = 8.4, 1.6 Hz, 4H), 3.87 (s, 3H), 2.62 (s, 6H), 1.54 (s, 6H). **¹³C NMR (100 MHz, CDCl₃)** δ : 160.5, 159.9, 148.4, 143.2, 137.4, 131.7, 129.0, 128.9, 126.6, 125.9, 125.9, 125.2, 120.6, 114.9, 55.3, 13.4, 13.2.




5,5-difluoro-10-(4-methoxyphenyl)-1,3,7,9-tetramethyl-2,8-bis(phenylsulfonyl)-5H-4λ⁴,5 λ⁴-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine (6): This compound was prepared following the oxidation method herein described. Purification by FCC (hexane/EtOAc) afforded product **6** (21.3 mg, 0.033 mmol, 67% yield) as an orange solid; **m.p.** (°C) = 198-200; **IR (solid, cm⁻¹)** ν : 2922 (m), 1738 (m), 1538 (s), 1464 (s), 1305 (s), 1150 (s), 1055 (m), 963 (m), 835 (w), 749 (w); **HRMS (ESI⁺)**: Calcd for C₃₂H₂₉BF₂N₂O₅S₂Na [M+Na]⁺ 657.1476, found 657.1467; **HRMS (ESI⁺)**: Calcd for C₃₂H₃₀BF₂N₂O₅S₂ [M+H]⁺ 635.1657, found 635.1657; **¹H NMR (400 MHz, CDCl₃)** δ : 7.83 (d, *J* = 7.5 Hz, 4H), 7.58 (t, *J* = 7.3 Hz, 2H), 7.50 (t, *J* = 7.5 Hz, 4H), 7.06 (q, *J* = 8.7 Hz, 4H), 3.88 (s, 3H), 2.88 (s, 6H), 1.71 (s, 6H). **¹³C NMR (100 MHz, CDCl₃)** δ : 161.2, 158.0, 147.1, 146.9, 142.6, 133.3, 131.8, 129.3, 128.7, 126.6, 125.0, 115.4, 102.3, 55.5, 14.3, 13.4. **¹⁹F NMR (470 MHz, CDCl₃)** δ : 143.11 (q, *J* = 31,7 Hz).

Synthesis of BODIPY 7




4-(methylthio)benzaldehyde (0.67 mL, 5.0 mmol) and 2,4-dimethylpyrrole (1.03 mL, 10.0 mmol) were mixed with a pestle and mortar. Trifluoroacetic acid (TFA) (5 drops) was added via a pipette, while the mixture was ground with the pestle for about 2 minutes. To the resulting paste, CHCl₃ (2.0 mL) was added, followed immediately by the addition of *p*-chloranil (1.81 g, 7.4 mmol). The purple paste was ground for 2 minutes, after which triethylamine (TEA) (6.0 mL, 43.0 mmol) was added via a syringe. The resulting dark brown paste was ground with the pestle for 3 minutes. Subsequently, BF₃·OEt₂ (6.0 mL, 47.4 mmol) was added slowly, dropwise, via a syringe and the mixture was ground for 2 minutes until a thick dark red paste was formed. The reaction mixture was dissolved in CHCl₃ (200 mL), transferred to a separation funnel, and washed with saturated Na₂CO₃ (3 × 200 mL) followed by brine (2 × 200 mL). The solvent was evaporated under reduced pressure and the crude solid was purified by column chromatography (silica gel) using hexane:chloroform (9:1) as the eluent to give the desired product 7.



5,5-difluoro-1,3,7,9-tetramethyl-10-(4-(methylthio)phenyl)-5H-4λ⁴,5

λ⁴dipyrrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine (7): Purification by FCC (hexane/CH₂Cl₂) afforded product **7** (778 mg, 2.1 mmol, 42% yield) as a pink solid; **m.p.** (°C) = 186-187; **IR (solid, cm⁻¹)** ν : 3021 (s), 1538 (s), 1460 (m), 1300 (s), 1158 (s), 1055 (w), 850 (m), 725 (m); **HRMS (ESI⁺)**: Calcd for C₂₀H₂₁BF₂N₂SNa [M+Na]⁺ 393.1384, found 393.1382; **HRMS (ESI⁺)**: Calcd for C₂₀H₂₂BF₂N₂S [M+H]⁺ 371.1564, found 371.1563; **¹H NMR (400 MHz, CDCl₃)** δ : 7.35 (d, *J* = 8.2 Hz, 2H), 7.19 (d, *J* = 8.2 Hz, 2H), 5.98 (s, 2H), 2.55 (d, *J* = 3.7 Hz, 9H), 1.43 (s, 6H). **¹³C NMR (100 MHz, CDCl₃)** δ : 155.6, 143.2, 140.9, 140.2, 131.5, 128.6, 126.6, 121.4, 119.0, 77.2, 29.9, 15.5, 14.8. **¹⁹F NMR (470 MHz, CDCl₃)** δ : 143.70 (q, *J* = 32.8 Hz).



5,5-difluoro-1,3,7,9-tetramethyl-10-(4-(methylsulfonyl)phenyl)-5H-4λ⁴,5

λ⁴dipyrrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine (8): This compound was prepared following the oxidation method herein described. Purification by FCC (hexane/EtOAc) afforded product **8** (25.7 mg, 0.064 mmol, 64% yield) as an orange solid; **m.p.** (°C) = 193-196; **IR (solid, cm⁻¹)** ν : 2922 (s), 1538 (s), 1464 (m), 1305 (s), 1150 (s), 1055 (w), 835 (m), 749 (m); **HRMS (ESI⁺)**: Calcd for C₂₀H₂₁BF₂N₂O₂SNa [M+Na]⁺ 425.1282, found 425.1281; **HRMS (ESI⁺)**: Calcd for C₂₀H₂₂BF₂N₂O₂S [M+H]⁺ 403.1463, found 403.1461; **¹H NMR (400 MHz, CDCl₃)** δ : 8.14 (t, *J* = 7.8 Hz, 2H), 7.58 (dd, *J* = 8.1, 3.9 Hz, 2H), 6.08 (s, 1H), 6.03 (s, 1H), 3.16 (d, *J* = 3.9 Hz, 3H), 2.59 (d, *J* = 5.7 Hz,

6H), 1.36 (t, $J = 6.1$ Hz, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ : 159.0, 156.6, 151.3, 144.3, 142.5, 141.8, 141.5, 141.1, 140.6, 138.9, 138.7, 130.8, 129.6, 129.5, 128.3, 128.2, 122.6, 121.8, 44.6, 14.7, 14.6, 12.3, 11.9.

Procedure for the recycling experiments

To a solution of **3a** (0.1 mmol) in $\text{H}_2\text{O}:\text{ACN}:\text{DCM}$ (2:1:1, 4 mL) was added RuCNT (0.1 mol%). The mixture was kept under vigorous stirring, and NaIO_4 (63.9 mg, 0.3 mmol) was added. The mixture was heated at 75 °C for 1 h, after this period, the reaction mixture was cooled to room temperature and methanol (4 mL) was added. The mixture was then transferred to *Eppendorf tube* (single tube) and centrifuged to give a pellet consisting of nanohybrid and inorganic salts. The supernatant was collected and the pellet was dispersed/centrifuged with fresh methanol (2×2 mL). All supernatants were combined, dried, and purified by chromatography over silica-gel, eluting with a gradient mixture of hexane/AcOEt with increasing polarity to quantitatively yield pure sulfone **4a**. The pellet was washed with water (2×2 mL) to remove inorganic salts from the nanohybrid. The recovered RuCNT catalyst was used without further treatment in subsequent recycling experiments.






Figure S1. Transmission electron microscopy image of the RuCNT hybrid.


Copies of NMR spectra of novel compounds




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1a**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1a**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1b**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1b**.




^1H NMR spectrum (400 MHz, CDCl_3) of compound **1c**.




^{13}C NMR spectrum (100 MHz, CDCl_3) of compound **1c**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1d**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1d**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1e**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1e**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1f**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1f**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1g**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1g**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1h**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1h**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1i**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1i**.



¹H NMR spectrum (400 MHz, CDCl₃) of compound **1j**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1j**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **1k**.



¹³C NMR spectrum (100 MHz, CDCl₃) of compound **1k**.





¹H NMR spectrum (400 MHz, CDCl₃) of compound **11**.





¹³C NMR spectrum (100 MHz, CDCl₃) of compound **11**.

8.79
8.77
8.74
8.72
8.35
8.34
8.33
8.31
8.30
8.29
8.09
8.07
8.05
7.90
7.89
7.88
7.87
7.85




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2a**.


181.0
180.8
138.3
135.9
135.1
134.9
134.6
134.0
133.4
132.0
128.0
127.3




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2a**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2b**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2b**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2c**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2c**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2d**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2d**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2e**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2e**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2f**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2f**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2g**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2g**.




^1H NMR spectrum (400 MHz, CDCl_3) of compound **2h**.




^{13}C NMR spectrum (100 MHz, CDCl_3) of compound **2h**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2i**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2i**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **2j**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **2j**.




$^1\text{H NMR}$ spectrum (400 MHz, CDCl_3) of compound **2k**.




$^{13}\text{C NMR}$ spectrum (100 MHz, CDCl_3) of compound **2k**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound 2I.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound 2I.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **4a**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **4a**.




^1H NMR spectrum (400 MHz, CDCl_3) of compound **4b**.





^{13}C NMR spectrum (100 MHz, CDCl_3) of compound **4b**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **4c**.




¹³C NMR spectrum (150 MHz, CDCl₃) of compound **4c**.







^1H NMR spectrum (400 MHz, CDCl_3) of compound **4e**.




^{13}C NMR spectrum (100 MHz, CDCl_3) of compound **4e**.




^1H NMR spectrum (400 MHz, CDCl_3) of compound 4f.




^{13}C NMR spectrum (100 MHz, CDCl_3) of compound 4f.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **5**.




¹³C NMR spectrum (100 MHz, CDCl₃) of compound **5**.




^1H NMR spectrum (400 MHz, CDCl_3) of compound **6**.



^{13}C NMR spectrum (100 MHz, CDCl_3) of compound **6**.




¹H NMR spectrum (400 MHz, CDCl₃) of compound **8**.



¹³C NMR spectrum (100 MHz, CDCl₃) of compound **8**.

Copies of HRMS of novel compounds




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:41:24 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2b**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 11:58:13 AM

Page 1 of 1

HRMS (ESI⁺) of compound **2c**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:19:47 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2d**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:22:59 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2e**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:28:50 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2g**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:35:42 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2h**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:32:15 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2i**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:08:27 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2j**.




Bruker Compass DataAnalysis 4.0

printed: 2/24/2019 12:25:59 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2k**.





Bruker Compass DataAnalysis 4.0



printed: 2/24/2019 12:06:30 PM

Page 1 of 1

HRMS (ESI⁺) of compound **2l**.



HRMS (ESI⁺) of compound **6**.



HRMS (ESI⁺) of compound **8**.

References

-
1. (a) G. Teverovskiy, D. S. Surry, S. L. Buchwald, *Angew. Chem. Int. Ed.*, 2011, **50**, 7312. (b) J. H. Clark, C. W. Jones, A. P. Kybett, M. A. McClinton, J. M. Miller, D. Bishop, R. J. Blade, *J. Fluorine Chem.*, 1990, **48**, 249.
 2. (a) M. J. Baena, P. Espinet, M. C. Lequerica, A. M. Levelut, *J. Am. Chem. Soc.*, 1992, **114**, 4182. (b) I. G. Dance, K. J. Fisher, R. M. H. Banda, M. L. Scudder, *Inorg. Chem.*, 1991, **30**, 183.
 3. G. A. M. Jardim, W. X. C. Oliveira, R. P. de Freitas, R. F. S. Menna-Barreto, T. L. Silva, M. O. F. Goulart, E. N. da Silva Júnior, *Org. Biomol. Chem.*, 2018, **16**, 1686.
 4. N. V. Ivashkina, V. S. Romanov, A. A. Moroz, M. S. Shvartsberg, *Russ. Chem. B.*, 1984, **33**, 2345.
 5. M. Gouda, M. Berghot, A. Shoeip, K. Elattar, A. E. G. Khalil, *Turk. J. Chem.*, 2010, **34**, 651-709.
 6. A. Kar, I. A. Sayyed, W. F. Lo, H. M. Kaiser, M. Beller, M. K. *Org. Lett.*, 2007, **9**, 3405-3408.
 7. M. Lutz, M. Wenzler, I. Likhovorik, *Synthesis.*, 2018, **50**, 2231-2234.
 8. G. Laudadio, N. J. Straathof, M. D. Lanting, B. Knoops, V. Hessel, T. Noël, T. *Green Chem.*, 2017, **19**, 4061-4066.
 9. J. Ahrens, B. Böker, K. Brandhorst, M. Funk, M. Bröring, *Chem. Eur. J.* 2013, **19**, 11382-11395.